EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Systemic Therapy for Metastatic Pancreatic Cancer—Current Landscape and Future Directions

Daniel Netto iD, Melissa Frizziero, Victoria Foy, Mairéad G McNamara iD, Alison Backen, Richard A Hubner

Current Oncology · 04.09.2024 · 31 (9) · 5206-5223

DOI: 10.3390/curroncol31090385 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 04.09.2024. Verfasst von Daniel Netto und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Christie NHS Foundation Trust, 550 Wilmslow Road, Manchester M20 4BX, UK. Hauptthemen laut MEDLINE: Pancreatic Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is a significant cause of cancer-associated mortality, with a rising global incidence. A paucity of strong predictive risk factors mean screening programmes are difficult to implement. Historically, a lack of identifiable and actionable driver mutations, coupled with a relatively immunosuppressed tumour microenvironment, has led to a reliance on cytotoxic chemotherapy. The NAPOLI-3 trial has reported data supporting consideration of NALIRIFOX as a new first-line standard of care. Kirsten Rat Sarcoma Virus (KRAS) G12D mutations are present in >90% of all PDAC’s; exciting breakthroughs in small molecule inhibitors targeting KRAS G12D may open new modalities of treatment, and therapies targeting multiple KRAS mutations are also in early clinical trials. Although immunotherapy strategies to date have been disappointing, combination with chemotherapy and/or small molecule inhibitors hold promise and warrant further exploration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsHumansNeoplasm MetastasisCarcinoma, Pancreatic DuctalImmunotherapy

Stichwörter der Autor:innen

KRASchemotherapymetastaticmolecular profilingpancreas

Autor:innen und Institutionen

  • The Christie NHS Foundation Trust, 550 Wilmslow Road, Manchester M20 4BX, UK.
  • Division of Cancer Sciences, University of Manchester, Oxford Road, Manchester M13 9PL, UK.

ORCID-Profile: Daniel Netto, Mairéad G McNamara

Zitieren

APA

Netto, D., Frizziero, M., Foy, V., McNamara, M. G., Backen, A., & Hubner, R. A. (2024). Systemic Therapy for Metastatic Pancreatic Cancer—Current Landscape and Future Directions. Current Oncology, 31(9), 5206-5223. https://doi.org/10.3390/curroncol31090385

Vancouver

Netto D, Frizziero M, Foy V, McNamara MG, Backen A, Hubner RA. Systemic Therapy for Metastatic Pancreatic Cancer—Current Landscape and Future Directions. Current Oncology. 2024;31(9):5206-5223. doi:10.3390/curroncol31090385

BibTeX
@article{Netto2024,
  author = {Netto, Daniel and Frizziero, Melissa and Foy, Victoria and McNamara, Mairéad G and Backen, Alison and Hubner, Richard A},
  title = {Systemic Therapy for Metastatic Pancreatic Cancer—Current Landscape and Future Directions},
  journal = {Current Oncology},
  year = {2024},
  volume = {31},
  number = {9},
  pages = {5206--5223},
  doi = {10.3390/curroncol31090385}
}
Kostenlos starten →